Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity

Andrew Huberman tells a16z’s Daisy Wolf that GLP-1 drugs could theoretically eradicate obesity and that wearable biology-writing tech is 5 years away.

• Retatrutide (GLP-3, Eli Lilly) enables up to one-third body weight loss with partial muscle sparing; already circulating via gray-market sources.
• Huberman predicts over half of Americans will use GLP-1 drugs within 5 years, most at lower-than-prescribed compounded doses.
• Melanotan causes permanent skin-color changes and priapism risk; Huberman calls it genuinely dangerous despite fat-loss and libido effects.
• Real-time cortisol sensing doesn’t exist yet; Huberman says getting a large morning cortisol spike that troughs by afternoon wins 90% of the health game.
• Stimulants (Adderall, modafinil) improve alertness, not focus per se — a WashU paper found they perform about as well as a good night’s sleep.
• Huberman personally banks exercise blood as a longevity play: infusions of one’s own post-exercise blood at 70 from samples taken at 50.
• Eye-targeted non-invasive neurostimulation (via glasses) is his top investment thesis for dialing cognitive states within the next decade.
• Huberman is using AI to decode octopus camouflage patterns as a proxy for internal states — attempting cross-species communication without forcing human behaviors onto the animal.

2026-03-09 · Watch on YouTube